Navigation Links
A gene that protects against colorectal cancers
Date:12/14/2011

The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.

The results of this study have been published as a Letter in the 11th December 2011 issue of the journal Nature.

The team led by Patrick Mehlen, Director of the DEVweCAN 'Laboratory of Excellence' at the Lyon Cancer Research Centre (CNRS/Inserm/Centre Lon Brard/Universit Claude Bernard 1), studies the cell death process (apoptosis) and, in particular, the mechanism that makes the cells understand that they should initiate a self-destruction process when they become abnormal. Patrick Mehlen's team suggested that this mechanism could operate via sentinels located on the surface of cells, which examine their environment. The scientists named these sentinels 'dependence receptors'.

The research team focused on this concept of 'dependence receptors'. When a cell receptor is associated with its ligand, the classic message indicates 'all is well', and leads to cell survival. On the other hand, when the receptor is deprived of its ligand, it can send a message leading to cell death. This mechanism is also called 'apoptosis.' When this is applied to cancer research, the absence of ligands could cause the death of cancer cells that proliferate in an anarchic manner.

In this study, Patrick Mehlen's team shows that the DCC gene (Deleted Colorectal Cancer), which codes for a 'dependence receptor', protects the organism from the onset of cancer by causing the death of cells that become cancerous. The researchers used a mouse model where the DCC gene has been genetically modified. The mutation of this dependence receptor prevents the induction of apoptosis. When the DCC gene is eliminated by mutation, the mouse spontaneously develops colon cancer.

'The organism is naturally protected from the development of cancers thanks to the presence of this tumour-suppressing gene. Unfortunately, certain cancer cells escape from this control by blocking this 'dependence receptor' mechanism. That is how we know that the DCC gene is extinguished in most human cancers,' explains Patrick Mehlen.

In the near future, this research work could lead to a new targeted treatment that aims to reactivate the death of the cancer cells to destroy breast cancer, lung cancer, etc. 'Our group has developed several candidate drugs that reactivate the cell death induced by the DCC receptor in animal models, and we hope to be able to carry out human clinical testing of these candidate drugs in three years' time,' concludes Patrick Mehlen.


'/>"/>

Contact: Inserm Presse
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Happiness Protects Your Heart
2. New Insurance Membership Program Protects Washington State Families Against High Cost of Emergency Medical Transports
3. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
4. Breastfeeding protects children against peptic ulcer bacterium
5. Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion
6. EarPeace Protects Hearing for Thousands at South by Southwest
7. A stress-response system in the ear protects against hearing loss
8. Study Challenges Notion That Moderate Drinking Protects the Heart
9. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
10. New Study Finds HPV Vaccine Protects Against Genital Warts
11. Widely used arthritis pill protects against skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... is proud to announce a new informational post on robotic hair transplantation. San ... Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five states ... And the need for advanced services is growing. , Project WE vs C ... in collaboration with their non-profit partners in their fight against cancer and in support ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... PA (PRWEB) , ... February 26, 2017 , ... ... and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. ... Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)... AUSTIN, Texas , Feb. 27, 2017  International Biophysics ... Austin, Texas , today announced a 34% revenue growth ... a 53% increase in unit sales.  This growth was fueled ... in addition to the expansion of its global ... Shockley, Jr., International Biophysics, CEO, "As we enter our 25 ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: